Endpoint Ventures

Indee Labs develops hardware and platform technologies for gene delivery to immune cells, with the aim of enabling the rapid development and scalable manufacture of gene-modified cell therapies, including CAR-T cells. The company focuses on non-viral delivery methods to introduce small molecules, nucleic acids, proteins, and gene-editing complexes into immune cells, supporting biopharmaceutical research and manufacturing while maintaining high cell viability and function. Its technology has progressed with collaboration from national facilities and through participation in biotech incubators and accelerators. Indee Labs maintains an international footprint, with an office in Sydney and lab space in Berkeley, reflecting its cross-regional development and manufacturing focus.

Shasqi, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2018. The company specializes in the development of its proprietary CAPAC (Click Activated Protodrugs Against Cancer) platform, which utilizes click chemistry for localized drug activation in oncology. This innovative approach allows for the activation of prodrugs directly at tumor sites by employing a polymer gel that concentrates the drug, minimizing systemic exposure and associated toxicity. Shasqi’s technology enables a powerful localized therapy when a click chemistry reagent is localized in the tumor area, activating the protodrug infused systemically. The efficacy of this platform has already been demonstrated in human applications, paving the way for future advancements in click-chemistry-based cancer therapies.

Viosera Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies to combat antibiotic resistance, particularly targeting methicillin-resistant Staphylococcus aureus (MRSA). Founded in July 2016, the company is headquartered in Sunnyvale, California, with additional operations in St. Louis, Missouri. Viosera's flagship product, VT1, is designed to treat MRSA bloodstream infections. The company employs artificial intelligence to identify and develop drug combinations that predict and block resistance evolution in both bacterial infections and cancer treatment. Through these advancements, Viosera aims to provide effective solutions that address the growing threat of antibiotic resistance, ultimately improving patient outcomes.

FidoCure develops AI-driven precision medicine for canine cancer. It analyzes data from naturally occurring canine tumors using next-generation sequencing and clinical information to build a proprietary learning database for cancer analysis. The company provides genomic sequencing services and targeted therapy recommendations to veterinarians, enabling personalized treatment plans. By linking veterinary and human oncology, FidoCure advances comparative oncology, aims to improve outcomes for dogs and to inform drug development that benefits both pets and people.

Synkrino Biotherapeutics is a biotechnology company focused on discovering and developing innovative drug targets derived from the immune systems of patients. The company is dedicated to creating novel therapeutics aimed at treating diseases driven by immune responses and inflammation. Utilizing its AI Immunology Discovery Engine, Synkrino employs neural networks and machine learning to analyze immune tissue, allowing for the repeatable identification of biologically-valid drug targets. This approach not only enhances the potential for effective treatments but also aims to improve patient outcomes. Additionally, Synkrino is working on a rapid, portable field test for the RNA virus responsible for COVID-19, adapting its analytical methods for public health screening in pediatric rheumatology and other critical health areas.

Founded in 2015, Meru Health develops a digital therapeutic program for individuals experiencing stress, depression, anxiety, and other mental health issues. The program, delivered via mobile app, combines licensed clinician support with cognitive behavioral therapy, sleep coaching, and nutrition guidance to improve mental well-being.

HelpWear develops a waterproof wearable device that monitors heart activity, detects heart attacks, and sends real-time alerts to medical facilities. Incorporated in 2015, the company is based in Toronto, Canada.

BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.

BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.